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FINE MAPPING OF A MAJOR QUANTITATIVE TRAIT LOCUS MEDIATING 
MULTIPLE OPIOID ADDICTION BEHAVIORS 
 
 
ALEXANDER LUONG 
ABSTRACT 
 Opioid addiction is a growing epidemic with no known genetic basis.  Mice 
represent a valuable tool that can be used to better understand the genetic components of 
opioid addiction by studying opioid induced behaviors such as locomotor activity.  The 
two closely related C57BL/6 substrains, C57BL/6J (B6J) and C57BL/6NJ (B6NJ), 
exhibit limited genetic diversity, yet display phenotypic differences when under the 
influence of oxycodone.  Quantitative trait locus (QTL) mapping, a discovery based 
approach to identifying genomic regions underlying statistical variation in complex traits, 
was used to identify a locus on distal chromosome 1 for oxycodone-induced locomotor 
activity and withdrawal.  F2 offspring from a cross utilizing these substrains that are 
homozygous B6J across the chromosome 1 QTL compared to offspring that are 
heterozygous display the same phenotypic differences as the parental strains, namely 
oxycodone-induced locomotor activity.  F2 mice were selected based on distal 
chromosome 1 genotypes and backcrossed to parental strain C57BL/6J to fine map the 
QTL interval.  Through family analysis, regions proximal to 167 Mb and distal to 187 
Mb have been ruled out as containing the QTL mediating oxycodone-induced locomotor 
activity.  Future studies should employ this same technique to fine map the QTL 
 vi 
mediating oxycodone withdrawal in order to differentiate whether it is one locus or two 
loci controlling these oxycodone induced behaviors.    
 vii 
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INTRODUCTION 
Background 
Worldwide, opioid dependence is the largest contributor to years lost in one’s life 
due to a disease (Degenhardt et al. 2013).  In 2014, 49.2% of all drug abuse deaths in the 
United States were attributable to opioid abuse (Laslo et al. 2017).  From 2007 to 2013, 
the number of users in the United States increased from 373,000 to 681,000 (Laslo et al. 
2017).  Recently, the state of Massachusetts has declared a state of public emergency in 
regards to the rising opioid epidemic (Department of Public Health 2014).  “Opioid” is a 
general term used to classify a group of highly addictive drugs, including both illicit (i.e. 
heroin) and prescription drugs, such as oxycodone, fentanyl, and morphine.  Opioid use 
disorder is classified by the Diagnostic and Statistical Manual of Mental Disorders as a 
chronic condition that is defined in part by the continued use opioids despite negative 
consequences in areas of life including one’s health, work, school, or home (American 
Psychiatric Association, 2013)  
The current forms of treatment for opioid addiction treat only symptoms or 
consequences of the diease rather than the disease itself.  One form of symptom treatment 
is opioid maintenance treatment (OMT), which is the daily use of an opioid agonist, (i.e. 
methadone), to limit cravings and withdrawal symptoms.  Methadone has been widely 
accepted as a standard form of treatment for opioid dependence by healthcare providers 
since the 1960s (Laslo et al. 2017).  As a consequence, users become dependent on a 
different synthetic opioid, while still facing risks of harmful respitatory depression and 
potential addiction/overdose (Laslo et al. 2017).  Another form of symptom treatment to 
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alleviate physiological effects of withdrawal involves the use of clonidine, an alpha 2 
adrenergic receptor agonist (Gowing et al. 2016).  While it does not help to satiate opioid 
cravings, it helps reduce physical symtoms of withdrawal such as anxiety, agitation, and 
muscle spasms (Capino et al. 2016).   
A major life-threatening consequence of opioid use is overdose, which is 
currently treated with the use of opioid antagonists, such as naloxone or naltrexone. 
These drugs are non-selective, specific opioid receptor antagonist (Lobmaier et al. 2016).  
Again, this form of treatment does not treat the diease itself but rather a side effect due to 
the disease.  It is clear that new forms of treatment, ones that tackle the disease rather 
than the symptoms of addiction, must be developed. 
 
Genetics of Opioid Addiction 
Opioid addiction is a complex disease that involves a multitude of factors 
including one’s susceptibility to the disease as well as environmental factors. The 
interaction of three major factors that contribute to the pathogenesis of opioid addiction:  
genetic factors (Kendler et al. 2003; Tsuang et al. 1996; Tsuang et al. 1998), drug-
induced neurobiological changes, and influence of other environmental factors besides 
drug exposure (e.g. early life trauma) (Nielsen and Kreek 2012).  Based on twin, family, 
and adoption studies, it has been shown that opioid abuse/dependence is 43-60% 
heritable but this genetic component is not yet well understood (Ho et al. 2010).  While 
genome wide association studies (GWAS) have been conducted in humans, there has 
been little success in identifying genes underlying drug addiction due to large number of 
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statistical tests required and the small effect sizes that can be expected from the 
contribution of common variants to complex diseases.  A human GWAS examining 
500,000 SNPs with a p = 0.05 could potentially give 25,000 false positives (Ho et al. 
2010).  As such, genome-wide statistical significance of p < 1 x 10-7 is typically used (Ho 
et al. 2010), however, that requires extremely large population sizes to achieve 
significance.  For example, a recent human GWAS which identified 108 significant loci 
associated with schizophrenia involved 36,989 cases and 113,075 controls 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014).   
 
Mouse Models to Study Genetics of Addiction 
While drug addiction is purely a human disease, mammalian models are a 
valuable tool that can be used to study addiction relevant phenotypes.  Mice in particular 
are especially valuable because 99% of mice genes have a direct human counterpart (Kile 
and Hilton 2005).  In addition, there are many practical reasons that make the use of mice 
advantageous- mice have shorter generation times than other mammals and can be bred 
easily, allowing for studies that require large population numbers.  Addiction is a 
complex disease that involves multitudes of variables, including environmental variables 
that are difficult to control for in humans.  In studies utilizing mammalian models, there 
is greater control over environmental factors such as housing, food, temperature, 
humidity, and light/dark cycles.   
All drugs of abuse share a common circuitry in the brain’s limbic system, with 
each drug activating specific dopaminergic transmissions to produce their effects (Nestler 
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2005).  In particular, opioids cause dopamine release in the nucleus accumbens (Di 
Chiara and Imperato 1988), an important area for reward learning in the brain (Flagel et 
al. 2011).  Opioids bind to mu opioid receptors on GABA-nergic interneurons in the 
ventral tegmental area (VTA), causing hyperpolarization (Johnson and North 1992).  This 
leads to a decrease in synaptic input that causes excitation of dopamine cells via 
disinhibition, leading to increased dopamine release.  The nucleus accumbens is involved 
in both locomotor activity and drug reward learning (Di Chiara and Imperato 1988; Wise 
and Bozarth 1987).  Therefore, locomotor activity (i.e. drug sensitivity) can sometimes be 
used as a proxy to identify common genetic factors involved in both locomotor activity 
and drug reward.  Sensitivity to the locomotor stimulant response to opioids is heritable 
(Phillips et al. 2008; Belknap et al. 1998; Oliverio et al. 1975; Gill and Boyle 2008; 
Philip et al. 2010).  Furthermore, variation in acute locomotor sensitivity in rodents and 
subjective drug euphoria in humans can predict susceptibility to drug-self administration 
as well as risk for drug dependence (Piazza et al. 2013; Haertzen et al. 1983). Therefore, 
drug sensitivity and drug reward share at least some common genetic factors.  
Furthermore, drug liking is predicative of future abuse (Haertzen et al. 1983).  Thus, 
understanding the genetic basic of opioid addiction would prove crucial in developing 
new treatments aimed at curbing opioid addiction.   
 
Conditioned Place Preference 
 Mammalian behavioral models can be used to study the rewarding (drug liking) 
effects of drugs (Koob and Volkow 2010).  In the conditioned place preference (CPP) 
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model, a mouse is confined to a chamber with two different “environments”.  On 
designated training days, the mouse is restricted to one environment and either given drug 
or saline.  After training, the mouse is allowed access to both environments and tested for 
association of drug with the drug-paired environment.  Preference for the drug-paired 
side is thought to represent the rewarding properties of the drug (conditioned place 
preference, CPP) (Bryant et al. 2014; Tzschentke 2007).  With this model, drug-induced 
locomotor activity and locomotor sensitization can be measured on training days.  CPP 
assessment can be measured both with and without the influence of drug, to determine 
state-dependent and state-independent preferences (Tzschentke 2007).   
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Figure 1: Place Conditioning Chamber and CPP Protocol 
 
(A) Two-chamber design with each chamber differentiated by floor texture.  Video 
recording from above and AnyMaze software used for video tracking allows for 
detection of numerous drug-related behaviors, such as rotations (Rot., defined as 
completion of unidirectional, circular sequence across four zones 1-2-3-4 or 3-2-1-4). 
 
(B) Schematic of nine day place conditioning protocol.  Mice are allowed access to both 
sides of chamber and assessed for initial preference on Day 1.  Days 2-5 are training 
days, where mice receive either drug or saline injections.  Days 6-7 are consolidation 
days, with mice being left undisturbed in home cages.  On Day 8 mice are assessed 
for final preference in drug free state.  On Day 9 mice are assessed for state-
dependent preference.  Rot. = rotation, D = day, Pref. = preference, SAL = saline, 
CPP/CPA = conditioned place preference, conditioned place aversion  
(Kirkpatrick and Bryant 2014) 
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Quantitative Trait Locus Mapping 
 Quantitative trait locus (QTL) mapping is an unbiased, discovery-based approach 
to identifying genomic regions and ultimately genetic variants underlying statistical 
variation in complex traits. This process identifies a QTL, an area of the genome that is 
associated with the phenotypic expression of complex traits (Tarantino and Eisener-
Dorman 2012).   Typically, QTL mapping is used to identify genotypic variation 
responsible for phenotypic variation in inbred strains (Tarantino and Eisener-Dorman 
2012).  An inbred strain is a mouse strain that has undergone brother-sister mating for at 
least 20 generations, resulting in genetically identical offspring.  Each individual within 
an inbred strain is genetically identical and thus, any phenotypic variation within an 
inbred strain is caused by environmental factors and any variation between inbred strains 
is caused by genetic factors. The C57BL/6 inbred mouse strain is the most widely used 
strain in biomedical research (Bryant 2011).  Two of its substrains, C57BL/6J (B6J) and 
C56BL/6NJ (B6NJ) are nearly genetically identical, yet display phenotypic variation for 
numerous complex traits.  When two inbred strains are crossed, the offspring will be 
heterozygous at every allele (F1 generation) (Figure 2).  F1 offspring are then bred 
together to create an F2 generation.  The genetic variation between strains can then be 
tracked using a set of polymorphic markers that distinguish the two strains.  Over time, 
the type of markers used has changed from restriction fragment length polymorphisms 
(RFLPs) to simple sequence length polymorphisms (SSLPs) to the more high throughput 
single nucleotide polymorphisms (SNPs) (Tarantino and Eisener-Dorman 2012).  Once 
genotypes and phenotypes have been collected, a statistical analysis can be run and a 
 8 
logarithm of odds (LOD) score is generated.  The score is a measurement of the strength 
of statistical association between phenotypic variance and genetic variance that is in 
linkage disequilibrium with the causal variant(s).  Essentially, the score compares the 
likelihood of obtaining test results due to linkage vs. obtaining the same results due to 
random chance.  A score greater than 3 generally translates to p = 0.05 (Nyholt 2000), 
and is considered evidence for significant linkage.  It indicates 1000 to 1 odds that the 
linkage observed did not occur by chance.  
 
Fine Mapping a Quantitative Trait Locus 
 Standard QTL crosses, such as an F2 intercross, usually yield genomic regions 
over 20 Mb due to the relatively low number of recombination events in these 
populations (Tarantino and Eisener-Dorman 2012).  A region this large could contain 
hundreds of genes and thousands of polymorphisms, making it difficult to identify the 
genetic variant responsible for the QTL.  Identification of the quantitative trait gene(s) 
(QTGs) typically requires refinement of the QTL interval.  Narrowing of this interval 
involves the use of specialized populations, namely congenic strains.  Congenic strains 
are made from repeatedly backcrossing an allele from a donor strain onto a recipient 
strain until only a small region of the QTL-containing donor strain chromosome is 
transferred into the recipient strain background (Tarantino and Eisener-Dorman 2012).  
This process usually takes at least 13 generations.  
Drawbacks of using congenic strains include the possibility of QTL effects 
disappearing during the construction of the congenic strain.  This would result if the QTL 
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is removed from a heterogeneous background, eliminating epistatic interactions that 
increase QTL effect size (Tarantino and Eisener-Dorman 2012).  A loss of QTL signal 
could also result if the QTL was actually composed of a group of smaller effect size 
QTLs that appear as a single peak in a F2 population (Tarantino and Eisener-Dorman 
2012; Bryant et al. 2012).  The major drawback of fine mapping via congenic strains is 
the time- and labor-intensive nature of backcrossing necessary to create a truly congenic 
strain, where the genome is isogenic at every point except for at the QTL interval.  
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Figure 2: Creating an F2 population 
 
Inbred strains (such as C57BL/6J) are created from brother-sister mating for at least 20 
generations, resulting in genetically identical offspring homozygous at every allele. Two 
inbred strains are then bred to create an F1 population heterozygous at every allele.  Non-
sibling F1 mice are bred to create an F2 population which contain one or two copies from 
each parental strain.  
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Identification of A QTL on Distal Chromosome 1 for Oxycodone Sensitivity and 
Withdrawal Using the Reduced Complexity Cross 
Our laboratory has recently identified phenotypic behavioral differences in the 
closely related C57BL/6J (B6J) and C57BL/6NJ (B6NJ) mice for opioid antagonist 
aversion behaviors (Kirkpatrick and Bryant 2014) and opioid agonist behaviors 
(Goldberg et al. 2017).  The B6J and B6NJ substrains exhibit significant differences in 
oxycodone (OXY) sensitivity, specifically distance traveled on Day 2 (D2) and 4 (D4) of 
the OXY place conditioning paradigm(Figure 3).  To determine the genetic component 
responsible for the observed differences, our laboratory generated an F2 cross of B6J and 
B6NJ, denoted as the reduced complexity cross (RCC).  We identified a region of distal 
chromosome 1 that was responsible for variation in OXY behavioral sensitivity (Figure 
4).  Similar to the parental strains, we identified that F2 mice that were homozygous B6J 
at this locus exhibited increased OXY-induced locomotor activity (i.e. sensitivity) 
compared to those that were heterozygous or homozygous B6NJ (Figure 4).  Specifically, 
F2 mice that were homozygous B6J displayed increased spins, rotations, and distance 
traveled on Days 2 and 4 (first and second exposure to OXY in the place conditioning 
paradigm) (Figure 4).  Interestingly, a QTL for opioid withdrawal utilizing the elevated 
plus maze (EPM), co-mapped to this same region (Figure 5/6).  Opioid withdrawal in 
mice leads to increased open arm time in the elevated plus maze (Hofford et al. 2009; 
Hodgson et al. 2008; Buckman et al. 2009).  By utilizing the RCC, we greatly decreased 
the potential number of variants responsible for variation in the behavior, however we 
were still left with an interval of 163-190 Mb.  Also interestingly, D2 OXY-induced 
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locomotor activity appears to exhibit Mendelian inheritance, meaning that one major 
locus likely underlies parental strain variation.  Strain accounts for 25.25% variance in 
phenotype in parental strains and parental strain genotype at this QTL locus accounts for 
19.16% variance in phenotype in the F2 population. Furthermore, a similar effect size was 
exhibited between the parental strains and F2 mice that are homozygous for the J vs. N 
alleles, providing further support for a Mendelian inheritance.   A Mendelian inheritance 
eliminates concerns regarding the potential for epistatic loci on other chromosomes and 
suggests that we can immediately begin fine mapping this locus by backcrossing F2 mice 
that are recombinant within the QTL interval.   
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Figure 3: B6J/B6NJ Parental Strain Distance Traveled  
 
Parental strain B6J displayed increased locomotor activity compared to B6NJ under the 
influence of OXY.  Strains displayed no differences under SAL control.  
 
SAL = saline, OXY = oxycodone, B6J = C57BL/6J, B6NJ = C57BL/6NJ 
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Figure 4: Locus on Chromosome 1 
Affects OXY Sensitivity  
 
(A) QTL plots for distance traveled, spins, and rotations on Days 2 and 4. 
(B) Effect plot showing effect of genotype at QTL peak on Day 2 distance traveled in 
OXY vs. SAL treated F2 mice. 
(C) - (G) Effect plots showing effect of genotype at QTL peaks for associated phenotypes 
on Days 2 or 4. 
 
BB = homozygous B6J, BN =  
heterozygous B6J/B6NJ, NN = homozygous B6NJ, LOD = logarithm of odds, cM = 
centimorgan, QTL = quantitative trait locus, SAL = saline, OXY = oxycodone (Goldberg 
et al. 2017)  
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Figure 5: Locus on Chromosome 1 Affects OXY Withdrawal 
 
(A) QTL plot for open arm time in elevated plus maze.   
(B) Effect plot showing effect of genotype on time spent in open arm of elevated plus 
maze in OXY vs. SAL treated F2 mice. 
 
BB = homozygous B6J, BN = heterozygous B6J/B6NJ, NN = homozygous B6NJ, LOD = 
logarithm of odds, cM = centimorgan, QTL = quantitative trait locus, SAL = saline, OXY 
= oxycodone (Goldberg et al. 2017) 
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Figure 6: QTL for OXY-Induced Locomotor Activity and OXY Withdrawal 
 
QTL plots for QTL(s) mediating OXY-induced locomotor activity and OXY withdrawal 
peaked in same region on distal chromosome 1.  LOD scores over 3 are considered 
evidence of significant linkage (Nyholt 2000).  
 
LOD = logarithm of odds, QTL = quantitative trait locus, OXY = oxycodone, D2 = day 2 
(Goldberg et al. 2017)  
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OBJECTIVES 
Fine Map Distal Chromosome 1 using F2 Recombinants  
The closely related C57BL/6J and C57BL/6NJ strains of mice are two inbred 
substrains from the C57BL/6 family.  Recently, our laboratory has identified phenotypic 
variation in OXY-induced locomotor activity in the OXY conditioned place preference 
assay (OXY-CPP, Figure 3).  Specifically, the strains showed variation in Day 2 and Day 
4 distance traveled, rotations, and spins.  Our laboratory mapped a QTL to distal 
chromosome 1 that is responsible for the variation in behavior.  While QTLs identified 
using an RCC are usually quite large (tens of MBs), the advantage is that the number of 
polymorphic genes and functional variants responsible for trait variation are several 
orders of magnitude lower (Kirkpatrick et al. 2016; Kumar et al. 2013).  For example, the 
DBA/2J mouse line and C57BL/6J differ by about 4 million SNPs (Keane et al. 2011) 
while C57BL/6J and C57Bl/6NJ differ by about 10,000 SNPs (Simon et al. 2013).  
Making the same comparison within the QTL interval on distal chromosome 1 (172 – 178 
Mb), 23,723 SNPs within genes differ between DBA/2J and B6J vs. 83 SNPs between 
B6J and B6NJ (Keane et al. 2011; Yalcin et al. 2011).  
To further fine map and narrow the QTL interval, we selected F2 recombinants 
within the QTL interval and backcrossed these mice to the parental strain B6J.  A B6J x 
B6NJ F2 intercross (referred to as the Reduced Complexity Cross, RCC) contains 
approximately 32,000 genetic variants, instead of 4-35 million when using other inbred 
strains (Keane et al. 2011). 
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This project will focus on fine mapping and narrowing the QTL interval that our 
laboratory identified for Day 2 OXY-induced locomotor activity.  First, a cross was 
created using closely related B6J and B6NJ mice.  B6J and B6NJ mice were bred to 
create an F1 population.  Non-sibling F1 offspring mice were then bred to make an F2 
generation (RCC).  Specific F2 offspring were then selected based on their distal 
chromosome 1 genotypes and backcrossed to B6J to generate offspring that were either 
homozygous B6J (J/J) or heterozygous (J/N) across distal chromosome 1.   
We have decided to focus on narrowing the QTL interval for Day 2 OXY-induced 
locomotor activity.  Because behavioral sensitivity is a Mendelian trait in the nearly 
isogenic background of the RCC, we assumed that only genotypes at distal chromosome 
1 affected trait variation, and thus ignored genotypes across the rest of the genome.  This 
allowed us to immediately begin fine mapping F2 recombinant mice, without the need for 
generations of backcrossing to first generate genome-wide isogenicity.   
We hypothesize that the F2 recombinant mice will display the same phenotypic 
variation as the B6J/B6NJ parental strains as well as the RCC F2 mice, in which mice 
possessing one copy of the NJ allele show decrease locomotor activity under the 
influence of OXY.  Furthermore, we hypothesize that we will fine map and narrow the 
QTL interval mediating this phenotype through the use of F2 recombinant mice.  
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METHODS 
Drugs 
 Oxycodone hydrochloride (OXY, Sigma-Aldrich, St. Louis, MO USA) was 
dissolved in sterilized physiological saline (0.9%) prior to systemic intra-peritoneal (i.p.) 
injections.  The OXY dose of 1.25 mg/kg was chosen based on preliminary studies on 
B6J and B6NJ (Figure 3).   
 
Environment and Housing 
 All experiments were conducted in strict accordance with National Institute of 
Health Guidelines for the Care and Use of Laboratory Animals and approved by the 
Boston University Institutional Animal Care and Use Committee.  Colony rooms were 
maintained on a 12:12 hour light-dark cycle.  Lights on at 0630 hours.  Mice were housed 
in same-sex groups of two to five mice per standard shoebox-sized cage.  Mice were fed 
standard laboratory chow and water available ad libitum except during testing.  Mice 
were 50-100 days old at the time of testing. 
 
Recombinant F2 Mice 
 Female C57BL/6J and male C57BL/6NJ mice were ordered from the Jackson 
Laboratory (Bar Harbor, ME, USA) at 7 weeks of age and were set up as F1 breeders.  
Non-sibling F1 offspring from these breeders were set up to breed B6J x B6NJ F2s.  We 
chose to fine map RCC F2 offspring because of their nearly isogenic background.  The 
B6J and B6NJ substrains differ at about only 10,000 SNPs across their genome (Simon et 
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al. 2013).  A B6JxB6NJ cross allows much of the genome to be eliminated when 
considering genes that underlie a QTL, an advantage other crosses utilizing different 
inbred strains do not have.  We selected F2 mice based on their specific genotypes at 
distal chromosome 1 and backcrossed them to B6J mice to generate offspring that were 
either homozygous B6J (J/J) or heterozygous (J/N) across various markers on distal 
chromosome 1 (160 Mb-186 Mb).  Assuming that Day 2 OXY-induced locomotor 
activity is a Mendelian trait, only genotypes at distal chromosome 1 (163-190 Mb) were 
considered as potentially being associated with changes in behavior.  Genotypes across 
the rest of the genome were disregarded.  
 To estimate sample size required to achieve 80% power (p < 0.05%) for fine 
mapping, we used the mean and standard deviations of OXY-induced locomotor activity 
based on genotype at the peak marker on chromosome 1 (rs51237371, J/J vs. J/N).  Based 
on an effect size Cohen’s d = 0.79 (N = 59 J/J, N = 105 J/N; 206 F2 mice total), we 
achieved 99.9% power to detect a significant difference (p < 0.05, two-tailed test).  Based 
on this effect size, 27 homozygous J/J and 27 heterozygous J/N would be required to 
achieve 80% power (p < 0.05, two-tailed test).  Therefore, we aimed for a sample size of 
27 mice per F2 recombinant strain. 
 
 
Behavioral Testing Apparatus  
 The behavioral apparatus consisted of an open field (40 cm length x 20 cm width 
x 45 cm tall; Lafayette Instruments, Lafayette, IN, USA) that was used for locomotor 
studies surrounded by a sound-attenuating chamber (MedAssociates, St. Albans, VT, 
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USA).  There were sixteen total apparatuses.  For the experiments, the apparatus was 
partitioned into two equal sized compartments using an ion transparent plastic black 
divider containing a mouse entryway (5 cm x 6.25 m).  This divider was flipped upside 
down during training to confine mice to one side of the testing apparatus.  Two different 
floor textures were used on each side of the apparatus to differentiate the two sides 
(Plaskolite Inc., Columbus, OH, USA).  Data from the apparatuses were recorded using a 
security camera system (Swann Communications, Melbourne, Australia).  The videos 
were then subjected to video tracking analysis (Anymaze, Stoelting, Wood Dale, IL, 
USA).  Video tracking allows to analysis of multiple variables that contribute to 
understanding drug-induced behaviors (Kirkpatrick and Bryant 2014) and the genetic 
components of these behaviors.  
 
Behavioral Phenotyping 
 This project focused only on fine mapping Day 2 OXY-induced locomotor 
activity.  An identical, yet truncated two day version of the place conditioned paradigm 
with 30 minute testing sessions was used (Figure 7).  Mice were habituated in testing 
room for a minimum of one hour prior to start of experiment.  Intra-peritoneal injections 
occurred immediately prior to mice being placed in the apparatus.  On Day 1, mice were 
injected with saline (SAL, 10ml/kg) and allowed open access to both sides of the 
apparatus.  On Day 2, mice were injected with OXY (1.25 mg/kg) and confined to the 
drug-paired side.  
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Figure 7: Abbreviated Two Day Paradigm 
 
For this project, an abbreviated two day paradigm adapted from our laboratory’s previous 
studies utilizing a nine day place conditioning paradigm was used.  Focusing only on Day 
2 OXY-induced locomotor activity rather than withdrawal behavior (which would require 
a four-week protocol) allowed us to fine map the locus in a high throughput manner.  
 
CPP/CPA = conditioned place preference, conditioned place aversion, SAL = saline 
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Behavioral Analysis 
 All behavioral analyses were run in R (https://www.r-project.org/) with a 
significance threshold set to p = 0.05.  Primary outcome measures included locomotor 
activity on Day 1 and Day 2.  Locomotor activity includes spins, rotations, and distance 
traveled.  Recombinations were tracked at each SNP marker and families were analyzed 
based on genotypes at each marker.  Families with similar genotypes were collapsed and 
analyzed together.   
 
DNA Sequencing 
 DNA was isolated from mice tail snips using the salting out method.  Using 
recently published sequencing results (Yalcin et al. 2011; Keane et al. 2011) (REL-1505), 
SNPs in the region of interest were determined and high confidence SNPs prioritized.  
DNA sequences for each SNP was obtained from the University of California, Santa Cruz 
Genome Browser (https://genome.ucsc.edu/).  DNA sequences were inputted into the 
Primer3 program (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) to design primers for 
regions flanking the SNPs (at least 50 bp upstream and 20 bp downstream).  Primers were 
ordered from Integrated DNA Technologies (Integrated DNA Technologies, Coralville, 
Iowa, USA) and used for polymerase chain reaction (PCR). DNA was diluted to 50 
ng/µL for PCR reactions.  PCR products were run on 1% agarose gel via electrophoresis.  
Successful PCR products (single, well-defined, bright band) were cut from a gel and 
extracted using QIAquick gel extraction kit (Qiagen, Valencia, CA, USA).  Samples were 
sent to Genewiz (Genewiz, South Plainfield, NJ, USA) for Sanger sequencing.  
Sequences were viewed using ABI Sequence Scanner (Applied Biosystems, Inc., Foster 
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City, CA, USA).  Following successful sequencing, custom Taqman SNP assays were 
designed (Life Technologies, Carslbad, CA, USA).  Chromosome 1 mice were genotyped 
at 7 SNPs (Table 1) within our region of interest with a mean distance of 4.25 cM 
(centimorgan) between markers.  Genomic coordinates are based on mm10 (Build 38), 
and marker position (cM) was estimated using the sex-averaged position using the Mouse 
Map Converter (http://cgd.jax.org/mousemapconverter/) (Cox et al. 2009).  
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Table 1: SNP Assays Across Distal Chromosome 1 
 
SNP markers used to monitor recombinations across distal chromosome 1, sorted by base 
pair/centimorgan position.  B6J SNP serves as reference allele and is compared to B6NJ 
allele when determining where recombination events occurred. 
 
cM = centimorgan, bp = basepair, SNP = single nucleotide polymorphism, B6J = 
C57BL/6J, B6NJ = C57BL6/NJ 
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RESULTS 
Replication of OXY QTL in F2 Recombinants 
Our laboratory previously mapped a QTL to distal chromosome 1 that is 
responsible for mediating OXY-induced locomotor activity.  To further fine map the 
QTL interval, F2 recombinant strains were created and tested in an abbreviated two day 
paradigm.   
In examining the phenotypes of the F2 recombinants, there were no differences in 
locomotor activity on day 1 (SAL), regardless of genotype (Figure 8A).  On day 2, mice 
that were homozygous B6J showed increased OXY-induced locomotor activity relative to 
mice that were heterozygous across distal chromosome 1 (Figures 8B).  The findings are 
less clear for spins and rotations, however, mice that were heterozygous across distal 
chromosome 1 clearly show decreased activity on day 2 (OXY) compared to day 1 
activity (SAL).  These findings coincide with our laboratory’s initial study, in which 
parental strain B6J mice exhibited increased OXY-induced locomotor activity compared 
to parental strain B6NJ (Figure 3).  They also coincide with our RCC findings, in which 
one copy of the NJ allele within the distal chromosome 1 locus was sufficient to decrease 
OXY-induced locomotor activity to a level similar to mice with two copies of the NJ 
allele (Figure 4). 
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Figure 8: Fine Mapping a QTL Mediating OXY-induced Locomotor Activity using 
Congenic Strains 
 
(A) Day 1 total distance traveled.  F2 recombinant mice received SAL (i.p.). 
(B) Day 2 total distance traveled.  F2 recombinant mice received OXY (1.25 mg/kg, i.p.). 
(C) Three original F2 strains used to backcross to parental B6J. Red dotted lines are 
locations of current SNP assays.  Black areas are homozygous J/J.  Grey areas are 
heterozygous J/N.  White areas are unknown genotypes. 
 
SAL = saline, OXY = oxycodone, B6J = C57BL/6J, SNP = single nucleotide 
polymorphism, i.p. = intra-peritoneal  
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Figure 9: OXY-Induced Locomotor Activity (Spins) 
 
(A) Day 1 total spins. F2 recombinant mice received SAL (i.p.).   
(B) Day 2 total spins. F2 recombinant mice received OXY (1.25 mg/kg, i.p.). 
 
B = Homozygous B6J (J/J genotype), H = Heterozygous (J/N genotype), SAL = saline, 
OXY = oxycodone, i.p. = intra-peritoneal 
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Figure 10: OXY-Induced Locomotor Activity (Rotations) 
 
(A) Day 1 total rotations.  F2 recombinant mice received SAL (i.p.). 
(B) Day 2 total rotations.  F2 recombinant mice received OXY (1.25 mg/kg, i.p.). 
 
B = Homozygous B6J (J/J genotype), H = Heterozygous (J/N genotype), SAL = saline, 
OXY = oxycodone, i.p. = intraperitoneal 
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Ruling Out the Region Distal to 187 Mb 
 The other goal of this project was to narrow down the QTL interval mediating 
OXY-induced locomotor activity on distal chromosome 1.  The original QTL interval 
identified was 163 - 190 Mb with three working SNP assays in this region (give Mb 
position).  Throughout the course of this project, we developed a total of 7 SNP assays 
within this region (table #).  Furthermore, we are able to conclusively rule out the region 
distal to 187 Mb as containing the causal variants.  We analyzed each congenic family 
based on their genotypes at each SNP assay.  Families with similar recombination events 
were collapsed together and analyzed as a single line.  Line 1A of Figure 11A represents 
this.  Line 1A represents offspring from one of the original three F2 mice that was 
selected to backcross to parental strain B6J to create the F2 recombinant lines.  Offspring 
were either homozygous J/J across the entire distal region of chromosome 1 (represented 
by black) or homozygous until 187 Mb, where they were then heterozygous J/N till the 
end of the chromosome.  Because offspring from both these lines did not display 
differences in locomotor activity (Figure 11B), we conclude that this area of the 
chromosome does not contain the QTL of interest.  
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Figure 11: Rule out Region Distal to 187 Mb 
 
(A) Line 1A represents the family analysis conducted to rule out the 187+ Mb distal 
region on chromosome 1 as containing the QTL.  Families that were homozygous B6J 
(J/J) (black) were compared to families that were homozygous B6J except from 187-
190 Mb, where they were heterozygous (J/N) (grey). White areas are unknown 
genotypes.  Red dotted lines represent current SNP assays used to monitor 
recombination events. 
 
(B) Locomotor activity on days 1/2 between lines compared.  n = 53 (J/J), n = 67 (J/N) 
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Ruling out the Proximal 163-167 Mb Region of the QTL 
 Once we ruled out the distal region from 187 Mb to the end of the chromosome 
from consideration we collapsed data across additional families and focused solely on 
genotypes from 163 to 187 Mb (Line 1 becomes Line 1B, Figure 12A).  Doing this, we 
were able to compare offspring that were homozygous across the region to offspring that 
were heterozygous at the proximal region of the chromosome (Figure 12A, Line 1B).  
Because there was no differences in OXY-induced locomotor activity between genotypes 
(Figure 12B), we conclude that the QTL responsible for OXY-induced locomotor activity 
is not located in any region proximal to 167 Mb on distal chromosome 1.   
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Figure 12: Rule out Region Distal to 163 Mb 
 
(A) Lines 1/1B represent family analysis conducted to rule out proximal region of 
chromosome as containing QTL.  After ruling out the distal 187+ Mb region, 
genotypes could be ignored from that region. This allows collapsing across families 
to analyze the proximal area (top line of Line 1 is collapsed with top line of 1B).  
Black areas are homozygous B6J (J/J), grey areas are heterozygous (J/N).  White 
areas are unknown genotypes.  Red dotted lines represent current SNP assays used to 
monitor recombination events. 
 
(B) Locomotor activity on days 1/2 between lines compared.  n = 9 (J/J), n = 24 (J/N) 
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DISCUSSION 
 This goal of this project was to fine map a quantitative trait locus responsible for 
opioid addiction-associated traits as measured via both acute behavioral sensitivity to the 
locomotor stimulant effect of OXY as well as spontaneous withdrawal following chronic 
OXY administration.  OXY-induced locomotor activity on Day 2 was assessed, including 
distance traveled, spins, and rotations. 
 Previously, our laboratory identified a phenotypic difference in OXY behavioral 
sensitivity in two B6 substrains, B6J and B6NJ.  Our laboratory then employed QTL 
mapping in the RCC of these two B6 substrains to identify a region on distal 
chromosome 1 that mediates OXY sensitivity (Figure 4).  We selected F2 offspring based 
on their genotypes at distal chromosome 1 and then backcrossed these mice to the B6J 
parental strain, creating several congenic strains (referred to as F2 recombinant lines).   
 Our laboratory also found that the QTL interval for OXY sensitivity overlapped 
with a QTL for the emotional-affective component of OXY withdrawal, measured via 
change in time spent in the open arms of the elevated plus maze (Figure 5).  The QTL 
intervals for these two phenotypes overlapped by approximately 10 Mb (171.0 – 180.5 
Mb), therefore it is possible that one locus is responsible for the differences in behavior.  
The 95% Bayes interval for these QTLs is still quite large (D2 Distance: Chr1 171.0 – 
181.3 Mb; Percent Open Arm Time: Chr1 151.7 – 180.5 Mb) and contains 83 SNPs (B6J 
vs. B6NJ) that could potentially be responsible for these phenotypes.  However, because 
the RCC utilized the closely related C57BL/6J and C57BL/6NJ strains which differ by 
only approximately 10,000 SNPs across their genome (Simon et al. 2013), there are much 
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fewer genetic variants in the QTL interval compared to a typical F2 cross. As a 
comparison, DBA/2J and C57BL/6J differ by approximately 4 million SNPs and 900,000 
indels across their genomes (Keane et al. 2011).   
 Additionally, our laboratory used the limited genetic diversity of the RCC to 
implement a novel approach to fine mapping Mendelian traits such as OXY behavioral 
sensitivity.  We selected F2 mice with recombinations in the QTL interval, and 
backcrossed them while ignoring genotype across the rest of the genome.  Because of the 
limited genetic diversity in the RCC and because we only identified a single locus 
accounting for most, of the genetic variance in OXY behavior, we reasoned that there 
would be minimal risk for epistatic interactions interfering with QTL detection following 
backcrossing and phenotyping of F2 recombinant lines.  This technique allowed us to 
replicate our QTL finding and define proximal and distal boundaries on the QTL.   
 While there is overlap between the QTL intervals for OXY sensitivity and 
withdrawal phenotypes, the question still remains as to whether one locus or two loci 
contribute to these phenotypes.  The interval for OXY withdrawal extends to 151.7 Mb 
on its proximal end, which is approximately 20 Mb past the proximal end of the QTL for 
OXY sensitivity (171.0 Mb).  One limitation of this study is the inability to test both 
phenotypes due to time constraints.  The amount of time required to breed and phenotype 
400 mice using a 4 week protocol (required for OXY-withdrawal) would have been too 
great.  Focusing on day 2 OXY-induced locomotor activity allowed us to fine map the 
QTL in a high throughput manner.  Thus, future studies are necessary to elucidate if there 
is a single QTL for OXY sensitivity and withdrawal or if there are two distinct loci.  
 36 
 While the distal end of chromosome 1 is a well-known QTL hotspot for 
neurobehavioral phenotypes (Mozhui et al. 2008), our laboratory has had trouble fine 
mapping the region of interest (171.0 – 180.3 Mb).  One issue has been finding primer 
sets that successfully amplified a single gel band that was then successfully Sanger-
sequenced for SNPs in the region.  Our laboratory has designed and tested over forty 
primer sets for our region of interest, with the majority of sets failing when running PCR 
products on a 1% agarose gel or when PCR products were extracted from gel and sent in 
for Sanger sequencing.  The primer set was considered failed when the gel gave multiple 
or undefined bands during imaging.  A primer set was also considered failed when the 
Sanger sequencing results failed.  Sanger sequencing results failed for a variety of 
reasons including SNPs sequencing: monomorphic, noisy with low confidence intervals 
for calls, or homomeric repeats before the SNP. 
 One theory that exists is that there may be a single master QTL on distal 
chromosome 1 that is responsible for several complex behavioral traits.  Phenotypes 
related to motor behavior, escape latency, emotionality, seizure susceptibility, and 
responses to various substances have all been studied with crosses involving C57BL/6J 
and one of six other inbred strains (Mozhui et al. 2008).  QTLs for each phenotype have 
mapped to distal chromosome 1, raising the question if there is a single master locus or a 
mixture of linked but functionally unrelated QTLs mediating the behaviors (Mozhui et al. 
2008).  One possible explanation is that there is a private SNP carried by B6J that none of 
the other inbred lines have, which is driving the different phenotypes. 
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 The ultimate goal of any QTL mapping study is to find the QTG that underlies the 
QTL.  While there has been advances in identifying QTLs for complex traits, moving 
from QTL to QTG remains the most critical, yet most challenging step.  Criteria for QTG 
validation include relating gene function to QTL phenotype, identifying allelic 
polymorphisms, or assessing gene homology to determine if sequence is conserved across 
species (Tarantino and Eisener-Dorman 2012).  Furthermore, ultimate QTG validation 
includes positional cloning and gene editing/replacement of the variant to demonstrate 
causality.  
In conclusion, we replicated our QTL findings from previous the F2 study which 
indicated that a QTL on distal chromosome 1 contains genetic variant(s) underlying 
OXY-induced locomotor activity.  F2 recombinant mice showed the same phenotypic 
variation as RCC and parental strain mice. Specifically, mice containing one copy of the 
NJ allele showed reduced OXY-induced locomotor activity.  Furthermore, we were able 
to use the nearly isogenic background of F2 recombinant mice to immediately fine map 
the distal region of chromosome 1 by reducing both a portion of the proximal and distal 
interval from consideration.  Based on family analysis, we conclude that the QTL lies in 
the region from 167 - 187 Mb. 
 
Future Directions  
 Our QTL encompasses the QTL neurobehavioral hotspot (172-178 Mb) (Mozhui 
et al. 2008) and we are focusing on introducing additional recombination events within 
this interval to further narrow the locus.  Future studies will include continuing to 
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monitor F2 recombinant mice for recombinations within the QTL interval.  Mice that 
possess such recombinations should be backcrossed to the B6J parental strain, in order to 
create additional F2 recombinant lines to further narrow the interval.  Once the QTL 
interval has been sufficiently narrowed, the same technique should be applied to fine map 
the QTL interval for OXY withdrawal, in order to determine if it is a single locus 
mediating both phenotypes, or if it is indeed two different loci responsible.  Finally, 
examination of mRNA transcription, differential exon usage, and protein levels of 
multiple brain regions will allow us to further prioritize candidate genes and potentially 
candidate nucleotides that we will test directly via gene editing. Following the successful 
identification of a QTG mediating multiple opioid phenotypes, an important future 
direction will be to test for the genetic association of this gene in humans as well as the 
potential association with other addictions. 
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